Subscribe

PuraPharm Corporation Limited (1498.HK)

HKD0.30 +0.00 (+0.00%)
HK HKSE Healthcare Drug Manufacturers - Specialty & Generic
Address Wireless Centre, Phase One
Tai Po, HK
CEO Yu Ling Chan
Website purapharm.com
IPO 2015-07-08
ISIN KYG7306Y1044

Explore sections of this company profile

Description

PuraPharm Corporation Limited, an investment holding entity, focuses on the research, development, manufacturing, and global distribution of concentrated Chinese medicine granules (CCMG) and various Chinese healthcare products across Hong Kong, Mainland China, and international markets. Its operations are structured into five key divisions: China CCMG, Hong Kong CCMG, Chinese Healthcare Products, Clinics, and Plantation. The company offers a range of over-the-counter health solutions under brand names such as PuraGold, Haveron, Oncozac, and Immuzac. Beyond product sales, PuraPharm provides a clinic management system for general Chinese medical practices and operates its own chain of Nong's Chinese medicine clinics, which deliver both traditional medical services and CCMG products. The company also oversees the cultivation and trade of raw Chinese herbs, in addition to manufacturing and selling traditional Chinese medicine decoction pieces. Complementing its product offerings, it delivers modernized Chinese medicine services and diagnostic consultations. PuraPharm distributes its goods to hospitals, healthcare institutions, medical professionals, and directly to consumers via an online store. The company currently manages 43 Nong's clinics in Hong Kong and one in Guangxi, China. Founded in 1998, its headquarters are located in Tai Po, Hong Kong.

Market Cap & Enterprise Value
Merger & Acquisition History

No mergers or acquisitions recorded for this company.

Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary Loading…
Indicator 1D1W2W3W1M
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
Averages
Trend
Price
Levels
Draw
HKD0.30 +0.00 (+0.00%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
597.2K
Beta
0.21
Float Shares
186.94M
Free Float %
44.7%
Price Performance
1D5D1M3M6M YTD1Y3Y5Y10YMax
+1.67% +1.67% +5.17% -11.59% -16.44% -14.08% -39.00% -68.88% -57.04% -90.56% -91.57%
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
vs.
Loading histogram data…

Revenue flow

Revenue by geography

Revenue by segment

From To

Revenue composition

From To

By product

By geography

Financial Statements

Income Statement

Balance Sheet

Cash Flow Statement

Key Metrics

Financial Ratios

Employees

Financial Growth (CAGR)

Market Data

Price Targets & DCF
Current price
0.30
DCF (Unlevered) 1.80 +511.7%
DCF (Levered) 2.76 +835.6%

DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.

Ratings Trend (MoM)
Rating 2024-11 Change
Strong Buy 0 0
Buy 0 0
Hold 0 0
Sell 0 0
Strong Sell 0 0
Quality scores
Altman Z-Score
0.26
Distress
Piotroski F-Score
5 / 9
Average
MOAT Score
2 / 10
No MOAT
Composite Rating
C+
Overall Score
2 / 5
Medium
DCF Score
4 / 5
High
ROE Score
1 / 5
Low
ROA Score
1 / 5
Low
D/E Score
1 / 5
Low
P/E Score
1 / 5
Low
P/Book Score
4 / 5
High
Operational MOAT
✗ Below peers
  • ✗
    Revenue growth Drug Manufacturers - Specialty & Generic: +6.8%
    -12.0% Q4'25: -22.6% (vs Q4'23)
  • ✗
    EPS growth Drug Manufacturers - Specialty & Generic: +16.5%
    +6.2% Q4'25: +82.2% (vs Q4'23)
  • ✗
    FCF margin FCF growth · Drug Manufacturers - Specialty & Generic: +32.3%
    -5.0% Q4'25: -8.7% (vs Q4'23)
  • ✗
    EBIT margin Drug Manufacturers - Specialty & Generic: +13.0%
    -4.8% Q4'25: -0.2% (vs Q4'23)
  • ✗
    ROIC Drug Manufacturers - Specialty & Generic: +6.5%
    -3.5% Q4'25: -0.3% (vs Q4'23)
  • ✗
    Share dilution Drug Manufacturers - Specialty & Generic: +0.0%
    +6.0% Q4'25: +12.0% (vs Q4'23)
  • ✗
    Debt / EBITDA Net debt/EBITDA · Drug Manufacturers - Specialty & Generic: -0.10×
    56.38× Q4'25: 10.10× (vs Q4'23)
Valuation Multiples From To
Price Forecast (3Y) From To
Model
Adjust
P/E
Theoretical Return — If Invested Today

* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.

DCF Interactive Model (UFCF)
Projection years:
Market assumptions
▶ WACC components (optional)
Ke (Cost of Equity) = Rf + β (0.21) × ERP
WACC = 27% × Ke + 73% × Kd (5.9%) × (1−t)

Modifying these values recalculates WACC automatically.

Business assumptions
—
Intrinsic value (base): 1.81 Current price: 0.30
Enterprise Value: — Equity Value: — Terminal Value: — TV as % of EV: —

Base values reflect the latest available data for this company and market conditions.

Consensus Estimates
Metric Dec 2015
actual 		Dec 2016
actual 		Dec 2017
actual 		Dec 2018
actual 		Dec 2019
actual 		Dec 2020
actual 		Dec 2021
actual 		Dec 2022
actual 		Dec 2023
actual 		Dec 2024
actual 		Dec 2026
1 Rev. Ana.
1 EPS Ana. 		Dec 2027
1 Rev. Ana.
1 EPS Ana. 		Dec 2028
1 Rev. Ana.
1 EPS Ana. 		Dec 2029
1 Rev. Ana.
1 EPS Ana. 		Dec 2030
1 Rev. Ana.
1 EPS Ana. 		Dec 2031
1 Rev. Ana.
1 EPS Ana. 		Dec 2032
1 Rev. Ana.
1 EPS Ana.
Revenue
473.90M
est: 456.00M (+3.9%)
535.99M
est: 525.30M (+2.0%)
591.57M
est: 596.70M (-0.9%)
745.50M
est: 694.30M (+7.4%)
695.88M
est: 761.10M (-8.6%)
601.82M
est: 645.30M (-6.7%)
659.59M
est: 742.60M (-11.2%)
448.07M
est: 862.00M (-48.0%)
406.86M
est: 998.40M (-59.2%)
382.09M
est: 998.40M (-61.7%)
596.70M
596.70M – 596.70M
-40.2% YoY
694.30M
694.30M – 694.30M
+16.4% YoY
761.10M
761.10M – 761.10M
+9.6% YoY
645.30M
645.30M – 645.30M
-15.2% YoY
742.60M
742.60M – 742.60M
+15.1% YoY
862.00M
862.00M – 862.00M
+16.1% YoY
998.40M
998.40M – 998.40M
+15.8% YoY
EBITDA
59.14M
est: 653.6K (+8,948.4%)
64.54M
est: 51.24M (+26.0%)
21.90M
est: 55.94M (-60.9%)
85.71M
est: 995.2K (+8,512.0%)
-122.19M
est: 1.09M (-11,300.6%)
114.67M
est: -149.73M (+176.6%)
-40.03M
est: 1.06M (-3,860.3%)
-46.34M
est: 1.24M (-3,850.3%)
-26.31M
est: -231.17M (+88.6%)
17.35M
est: 155.04M (-88.8%)
92.66M
92.66M – 92.66M
-40.2% YoY
107.81M
107.81M – 107.81M
+16.4% YoY
118.19M
118.19M – 118.19M
+9.6% YoY
100.21M
100.21M – 100.21M
-15.2% YoY
115.31M
115.31M – 115.31M
+15.1% YoY
133.86M
133.86M – 133.86M
+16.1% YoY
155.04M
155.04M – 155.04M
+15.8% YoY
EBIT
46.14M
est: -42.79M (+207.8%)
48.00M
est: 59.86M (-19.8%)
-2.88M
est: 58.52M (-104.9%)
48.41M
est: -65.15M (+174.3%)
-188.95M
est: -71.42M (-164.6%)
67.05M
est: -60.55M (+210.7%)
-90.17M
est: -69.68M (-29.4%)
-95.00M
est: -80.88M (-17.4%)
-74.91M
est: -247.33M (+69.7%)
-18.25M
est: 101.02M (-118.1%)
60.38M
60.38M – 60.38M
-40.2% YoY
70.25M
70.25M – 70.25M
+16.4% YoY
77.01M
77.01M – 77.01M
+9.6% YoY
65.29M
65.29M – 65.29M
-15.2% YoY
75.14M
75.14M – 75.14M
+15.1% YoY
87.22M
87.22M – 87.22M
+16.1% YoY
101.02M
101.02M – 101.02M
+15.8% YoY
Net Income
28.46M
est: 67.16M (-57.6%)
32.16M
est: 33.82M (-4.9%)
1.89M
est: 39.21M (-95.2%)
20.81M
est: 29.85M (-30.3%)
-227.26M
est: 11.19M (-2,130.4%)
31.71M
est: 11.85M (+167.6%)
-121.88M
est: 23.70M (-614.2%)
-120.21M
est: 35.55M (-438.1%)
-106.08M
est: -297.48M (+64.3%)
-35.44M
est: 46.06M (-176.9%)
67.24M
67.24M – 67.24M
+46.0% YoY
31.64M
31.64M – 31.64M
-52.9% YoY
11.86M
11.86M – 11.86M
-62.5% YoY
12.56M
12.56M – 12.56M
+5.9% YoY
25.13M
25.13M – 25.13M
+100.0% YoY
37.69M
37.69M – 37.69M
+50.0% YoY
46.06M
46.06M – 46.06M
+22.2% YoY
SGA
259.59M
est: 284.68M (-8.8%)
308.38M
est: 308.48M (0.0%)
398.74M
est: 376.00M (+6.0%)
447.02M
est: 433.45M (+3.1%)
454.69M
est: 475.15M (-4.3%)
352.79M
est: 402.86M (-12.4%)
380.28M
est: 463.60M (-18.0%)
325.84M
est: 538.14M (-39.5%)
263.18M
est: 602.26M (-56.3%)
223.39M
est: 627.75M (-64.4%)
375.18M
375.18M – 375.18M
-40.2% YoY
436.55M
436.55M – 436.55M
+16.4% YoY
478.55M
478.55M – 478.55M
+9.6% YoY
405.74M
405.74M – 405.74M
-15.2% YoY
466.92M
466.92M – 466.92M
+15.1% YoY
541.99M
541.99M – 541.99M
+16.1% YoY
627.75M
627.75M – 627.75M
+15.8% YoY
EPS
0.15
est: 0.17 (-11.8%)
0.14
est: 0.18 (-24.0%)
0.01
est: 0.16 (-95.1%)
0.08
est: 0.08 (+11.7%)
-0.82
est: 0.03 (-2,994.2%)
0.09
est: 0.03 (+185.0%)
-0.31
est: 0.06 (-616.7%)
-0.30
est: 0.09 (-433.3%)
-0.27
est: 0.11 (-345.5%)
-0.09
est: 0.11 (-181.5%)
0.16
0.16 – 0.16
+46.0% YoY
0.08
0.08 – 0.08
-52.9% YoY
0.03
0.03 – 0.03
-62.5% YoY
0.03
0.03 – 0.03
+5.9% YoY
0.06
0.06 – 0.06
+100.0% YoY
0.09
0.09 – 0.09
+50.0% YoY
0.11
0.11 – 0.11
+22.2% YoY
Historical Ratings (3M)
Date Rating Overall DCF ROE ROA D/E P/E P/B
2026-05-29 C+ 2/5 4/5 1/5 1/5 1/5 1/5 4/5
2026-05-28 C+ 2/5 4/5 1/5 1/5 1/5 1/5 4/5
2026-05-27 C+ 2/5 5/5 1/5 1/5 1/5 1/5 4/5
2026-05-26 C+ 2/5 5/5 1/5 1/5 1/5 1/5 4/5
2026-05-22 C+ 2/5 5/5 1/5 1/5 1/5 1/5 4/5
2026-05-21 C+ 2/5 5/5 1/5 1/5 1/5 1/5 4/5
2026-05-20 C+ 2/5 5/5 1/5 1/5 1/5 1/5 4/5
2026-05-19 C+ 2/5 4/5 1/5 1/5 1/5 1/5 4/5
2026-05-18 C+ 2/5 4/5 1/5 1/5 1/5 1/5 4/5
2026-05-15 C+ 2/5 4/5 1/5 1/5 1/5 1/5 4/5
2026-05-14 C+ 2/5 4/5 1/5 1/5 1/5 1/5 4/5
2026-05-13 C+ 2/5 4/5 1/5 1/5 1/5 1/5 4/5
2026-05-12 C+ 2/5 4/5 1/5 1/5 1/5 1/5 4/5
2026-05-11 C+ 2/5 4/5 1/5 1/5 1/5 1/5 4/5
2026-05-08 C+ 2/5 4/5 1/5 1/5 1/5 1/5 4/5
2026-05-07 C+ 2/5 4/5 1/5 1/5 1/5 1/5 4/5
2026-05-06 C+ 2/5 4/5 1/5 1/5 1/5 1/5 4/5
2026-05-05 C+ 2/5 4/5 1/5 1/5 1/5 1/5 4/5
2026-05-04 C+ 2/5 4/5 1/5 1/5 1/5 1/5 4/5
2026-04-30 C+ 2/5 4/5 1/5 1/5 1/5 1/5 4/5
2026-04-29 C+ 2/5 4/5 1/5 1/5 1/5 1/5 4/5
2026-04-28 C+ 2/5 4/5 1/5 1/5 1/5 1/5 4/5
2026-04-27 C+ 2/5 4/5 1/5 1/5 1/5 1/5 4/5
2026-04-24 C+ 2/5 4/5 1/5 1/5 1/5 1/5 4/5
2026-04-23 C+ 2/5 4/5 1/5 1/5 1/5 1/5 4/5
2026-04-22 C+ 2/5 4/5 1/5 1/5 1/5 1/5 4/5
2026-04-21 C+ 2/5 4/5 1/5 1/5 1/5 1/5 4/5
2026-04-20 C+ 2/5 4/5 1/5 1/5 1/5 1/5 4/5
2026-04-17 C+ 2/5 4/5 1/5 1/5 1/5 1/5 4/5
2026-04-16 C+ 2/5 4/5 1/5 1/5 1/5 1/5 4/5

Owner Earnings

Owner's Earnings (history) From To
Owner alignment
Owner's Earnings TTM
-2.41M
OE per share TTM
0.01
Owner's Yield
-1.78%
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
84.8%

Ownership Overview

Ownership breakdown

Ownership breakdown not available.

At a glance
Institutional holders
—
Total invested
—
Insider transactions (90d)
0
Beneficial owners (>5%)
0
Beneficial owners (>5%)

No beneficial ownership filings recorded.

Institutional Activity (13F)

Institutional ownership trend

Institutional history not available.

Top institutional holders

Top holders not available.

ETF Ownership

Top ETFs holding this stock

This company is not held by any ETF in our universe.

Insider Activity

Insider Activity — Latest Quarter

No insider activity available.

Insider buys vs sells (history)

Insider history not available.

Recent insider transactions

No recent insider transactions.

Executive team

Top executives
EBIT / Employee
-33.9K
Shares Outstanding
418.57M

Executive compensation

Executive compensation (annual)

Executive compensation not available.

CEO compensation breakdown

No CEO compensation history available.

Proxy statements

Proxy statements (DEF 14A)

No proxy statements available for this company yet.

Recent SEC filings

Recent SEC filings

No SEC filings available for this company yet.

Executive team

NameTitleCompensationGender
Yu Ling Chan Founder, Chairman & Chief Executive Officer 4M male
Kam Biu Tsoi Executive Director 724.0K —
Yee Wai Man Executive Director 724.0K female
Charmayne Chan Company Secretary — female
Jian Zhou Nanning Production Director — female
ESG Score History

No data available for this company.

Senate Trading Activity

No Senate trading activity found for this company.

House Trading Activity

No House trading activity found for this company.

Market share among peers
Peer comparison — filtered group (TTM)
Your opinion

Share your view on this stock and instantly see how the community has voted over the last 6 months.

These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.

Dividend yield history

Dividend history

Earnings history

Earnings reports

Stock splits

Related companies

Largest companies in Drug Manufacturers - Specialty & Generic